Sprintec and Focal segmental glomerulosclerosis - a phase IV clinical study of FDA data

Summary:

We study 7,183 people who take Sprintec (ethinyl estradiol; norgestimate) or have Focal segmental glomerulosclerosis. No report of Focal segmental glomerulosclerosis is found in people who take Sprintec.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Sprintec?

Sprintec has active ingredients of ethinyl estradiol; norgestimate. It is often used in birth control. eHealthMe is studying from 4,397 Sprintec users. Check the latest studies of Sprintec.

What is Focal Segmental Glomerulosclerosis?

Focal segmental glomerulosclerosis (scar tissue that forms in parts of the kidney called glomeruli) is found to be associated with 192 drugs and 390 conditions by eHealthMe. Check the latest studies of Focal segmental glomerulosclerosis.

On Feb, 10, 2026

No report is found.

Do you take Sprintec and have Focal segmental glomerulosclerosis?

- Check whether Focal segmental glomerulosclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sprintec:

Sprintec (4,397 reports)

Focal segmental glomerulosclerosis treatments and more:

Focal segmental glomerulosclerosis (2,786 reports)

How severe was Focal segmental glomerulosclerosis and when was it recovered:

Focal segmental glomerulosclerosis in Sprintec

Expand to all the drugs that have ingredients of ethinyl estradiol; norgestimate:

Focal segmental glomerulosclerosis and drugs with ingredients of ethinyl estradiol; norgestimate (1 reports)

Browse all side effects of Sprintec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Focal segmental glomerulosclerosis:

Focal segmental glomerulosclerosis

Browse all the conditions that are associated with Focal segmental glomerulosclerosis:

Focal segmental glomerulosclerosis

How the study uses the data?

The study uses data from the FDA. It is based on ethinyl estradiol; norgestimate (the active ingredients of Sprintec) and Sprintec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.